Elevated Metals in Plasma, Urine Linked to ALS Risk, Survival

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Aug. 9, 2024 -- Elevated metal levels in plasma and urine are associated with amyotrophic lateral sclerosis (ALS) risk and survival, according to a study published online Aug. 6 in the Journal of Neurology, Neurosurgery & Psychiatry.

Dae-Gyu Jang, Ph.D., from the University of Michigan in Ann Arbor, and colleagues examined associations of metal measures in plasma and urine with ALS risk and survival. The association between exposure mixtures and ALS risk and survival and exposure source was examined using environmental risk scores (ERS). ALS- and metal-polygenic risk scores (PGS) were also constructed.

Plasma and urine samples were included for 454 ALS patients and 294 controls. The researchers observed significant associations for elevated levels of individuals metals, including copper, selenium, and zinc, with ALS risk and survival. ERS representing metal mixtures was strongly associated with ALS risk (odds ratios, 2.95 and 3.10 for plasma and urine, respectively) and with poorer ALS survival (hazard ratios, 1.37 and 1.44 for plasma and urine, respectively). The significance of the association of metals with ALS risk and survival was not altered by the addition of ALS-PGS or metal-PGS. Elevated ERS was seen in association with occupations with high potential metal exposure. Occupational and nonoccupational exposures to metals were associated with measured plasma and urine metal levels.

"We demonstrate that metal mixtures, as represented by cumulative ERS, associate with increased ALS risk and reduced ALS survival, regardless of genetic predisposition. These associations correlate with self-reported occupational metal exposure," the authors write. "Overall, these results offer valuable insights into the complexities of ALS pathogenesis."

Two authors are listed as inventors on a patent titled "Methods for Treating Amyotrophic Lateral Sclerosis" that targets immune pathways for use in ALS therapeutics; one author disclosed ties to Evidera.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-08-10 01:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords